Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp (Nasdaq: OPRX) announced a remarkable 257% revenue growth, attributed to brand acquisition and product adoption, during the recent Deloitte Technology Fast 500 ranking announcement.
CEO William Febbo expressed confidence in the company’s growth trajectory, emphasizing their position in the digital point-of-care sector. The Deloitte award is a recognition of the top 500 fastest-growing tech companies in North America, showcasing OptimizeRx's robust performance from 2017 to 2020.
OptimizeRx Corp (Nasdaq: OPRX) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place from November 22 to December 2, 2021. The management team will engage in presentations available to registered attendees and hold 1x1 meetings through the conference platform. OptimizeRx is known for its point-of-care technology solutions aimed at improving patient engagement and therapy adherence, reaching over 60% of U.S. healthcare providers through its therapy initiation system.
OptimizeRx Corp. (Nasdaq: OPRX) is hosting its second annual Innovate4Outcomes event on December 9, 2021, from 1:00 PM to 4:30 PM ET. This virtual workshop aims to address patient access and support challenges in U.S. healthcare, bringing together pharmaceutical executives, healthcare providers, and advocacy leaders. The event will feature collaborative sessions to develop actionable solutions for systemic healthcare challenges. Notable advocacy groups like I AM ALS and RESOLVE will participate, showcasing their experiences to shape better patient outcomes.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 53% revenue increase to $16.1 million for Q3 2021, compared to $10.5 million in Q3 2020. Year-to-date revenue rose 52% to a record $41.0 million. Gross profit grew 51% to $9.1 million, though gross profit margin slightly decreased to 56.3%. The company achieved a non-GAAP net income of $1.6 million, or $0.09 per share. Cash and equivalents increased to $85.0 million. The number of brands utilizing its solutions rose to 182 from 140 in the previous quarter.
OptimizeRx Corp (Nasdaq: OPRX) released an analysis highlighting the barriers to therapy initiation and persistence for multiple sclerosis (MS) patients. The research underscores the significance of early treatment, which can slow disease progression and mitigate new brain damage. Challenges such as misdiagnosis and high costs hinder timely treatment. The analysis suggests that leveraging real-world data and AI-driven solutions could enhance diagnosis and support for patients, ultimately improving adherence to therapy. The median annual cost of branded disease-modifying therapies exceeds $90,000, creating financial barriers.
OptimizeRx Corp. (Nasdaq: OPRX) will hold a conference call on November 9, 2021, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The call will include a Q&A session and will be available via webcast. OptimizeRx offers digital health solutions connecting healthcare providers and patients, with a focus on therapy initiation and adherence programs. The company emphasizes its AI-driven marketing efforts to enhance patient engagement and treatment adherence.
OptimizeRx Corp. (Nasdaq: OPRX) announced that CEO Will Febbo will participate in a presentation and fireside chat at the Credit Suisse 30th Annual Healthcare Conference from November 8-11, 2021. The presentation is scheduled for November 11, 2021, at 11:20 A.M. (Track 2), and will be webcast live. OptimizeRx provides point-of-care technology solutions designed to improve patient therapy adherence by connecting healthcare providers and patients. For more details, visit the company’s investor relations page.
OptimizeRx Corp. (Nasdaq: OPRX) announced the appointment of Edward Stelmakh as the new chief financial officer (CFO) and chief operating officer (COO), effective October 11, 2021. He succeeds Doug Baker, who will remain as executive vice president of finance and accounting. Stelmakh brings over 30 years of experience in finance and operations, notably from Otsuka America Pharmaceuticals. CEO Will Febbo highlighted Stelmakh's expertise as crucial for the company's growth, particularly in enhancing customer relations and operational scalability amidst the healthcare industry's shift toward technology solutions.
OptimizeRx Corp. (NASDAQ: OPRX) is set to replace Lydall Inc. (NYSE: LDL) in the S&P SmallCap 600 index effective October 4, 2021. This change is occurring as Clearlake Capital Group is acquiring Lydall, with the deal expected to close around October 1. This addition marks a significant milestone for OptimizeRx, aligning it with a key financial benchmark, while Lydall will be removed from the index.
